Cargando…

Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial

PURPOSE: To evaluate the clinical efficacy and safety of propylene glycol/hydroxypropyl-guar (PG-HPG)-based nanoemulsion (Systane(®) Complete) lubricant eye drops in participants with dry eye disease (DED). PARTICIPANTS AND METHODS: In this phase IV, open-label, single-arm, interventional, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeu, Elizabeth, Silverstein, Steven, Guillon, Michel, Schulze, Marc-Matthias, Galarreta, David, Srinivasan, Sruthi, Manoj, Venkiteshwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478376/
https://www.ncbi.nlm.nih.gov/pubmed/32943837
http://dx.doi.org/10.2147/OPTH.S261318
_version_ 1783580036811456512
author Yeu, Elizabeth
Silverstein, Steven
Guillon, Michel
Schulze, Marc-Matthias
Galarreta, David
Srinivasan, Sruthi
Manoj, Venkiteshwar
author_facet Yeu, Elizabeth
Silverstein, Steven
Guillon, Michel
Schulze, Marc-Matthias
Galarreta, David
Srinivasan, Sruthi
Manoj, Venkiteshwar
author_sort Yeu, Elizabeth
collection PubMed
description PURPOSE: To evaluate the clinical efficacy and safety of propylene glycol/hydroxypropyl-guar (PG-HPG)-based nanoemulsion (Systane(®) Complete) lubricant eye drops in participants with dry eye disease (DED). PARTICIPANTS AND METHODS: In this phase IV, open-label, single-arm, interventional, multicenter study, adult participants with DED – subtyped into aqueous deficient, evaporative, and mixed dry eye – were instructed to instill one drop of PG-HPG in each eye twice a day for 28 days. Endpoints included change from baseline in tear film break-up time (TFBUT) (primary) and ocular discomfort visual analog scale (VAS) score at Day 14 and TFBUT at Day 28 (secondary). Safety was assessed throughout the study. Data were analyzed for overall patient cohort and by DED subtypes. RESULTS: A total of 134 participants received treatment (mean age: 56.6 years; female: 75.4%). At Day 14, the mean (standard deviation [SD]) TFBUT increased from 2.6 (1.00) seconds at baseline to 4.2 (2.92) seconds (mean change: 1.5 [2.80] seconds); median change was 0.8 seconds (95% CI: 0.52, 1.19) for the overall cohort; the change was maintained at Day 28 (mean change: 1.4 (2.80) seconds, median change: 0.8 seconds (95% CI: 0.49, 1.17). Subgroup analysis showed a mean change (SD) from baseline in TFBUT of 1.1 (2.41) seconds for aqueous deficient, 2.4 (3.17) seconds for evaporative, and 1.2 (2.63) seconds for mixed dry eye at Day 14, respectively. The ocular discomfort VAS score improved (decreased) from baseline at Day 14 (mean [SD] change: −17.3 [24.80]) for the overall cohort, −22.0 [21.73] for aqueous deficient, −17.6 [24.17] for evaporative and −13.1 [27.49] for mixed dry eye subgroups). Adverse events (AEs) were reported in 9 (6.7%) participants. No serious AEs were reported during the study. CONCLUSION: Our study findings demonstrated that PG-HPG-based nanoemulsion lubricant eye drops were effective and well tolerated in participants with DED and all of its subtypes.
format Online
Article
Text
id pubmed-7478376
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74783762020-09-16 Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial Yeu, Elizabeth Silverstein, Steven Guillon, Michel Schulze, Marc-Matthias Galarreta, David Srinivasan, Sruthi Manoj, Venkiteshwar Clin Ophthalmol Original Research PURPOSE: To evaluate the clinical efficacy and safety of propylene glycol/hydroxypropyl-guar (PG-HPG)-based nanoemulsion (Systane(®) Complete) lubricant eye drops in participants with dry eye disease (DED). PARTICIPANTS AND METHODS: In this phase IV, open-label, single-arm, interventional, multicenter study, adult participants with DED – subtyped into aqueous deficient, evaporative, and mixed dry eye – were instructed to instill one drop of PG-HPG in each eye twice a day for 28 days. Endpoints included change from baseline in tear film break-up time (TFBUT) (primary) and ocular discomfort visual analog scale (VAS) score at Day 14 and TFBUT at Day 28 (secondary). Safety was assessed throughout the study. Data were analyzed for overall patient cohort and by DED subtypes. RESULTS: A total of 134 participants received treatment (mean age: 56.6 years; female: 75.4%). At Day 14, the mean (standard deviation [SD]) TFBUT increased from 2.6 (1.00) seconds at baseline to 4.2 (2.92) seconds (mean change: 1.5 [2.80] seconds); median change was 0.8 seconds (95% CI: 0.52, 1.19) for the overall cohort; the change was maintained at Day 28 (mean change: 1.4 (2.80) seconds, median change: 0.8 seconds (95% CI: 0.49, 1.17). Subgroup analysis showed a mean change (SD) from baseline in TFBUT of 1.1 (2.41) seconds for aqueous deficient, 2.4 (3.17) seconds for evaporative, and 1.2 (2.63) seconds for mixed dry eye at Day 14, respectively. The ocular discomfort VAS score improved (decreased) from baseline at Day 14 (mean [SD] change: −17.3 [24.80]) for the overall cohort, −22.0 [21.73] for aqueous deficient, −17.6 [24.17] for evaporative and −13.1 [27.49] for mixed dry eye subgroups). Adverse events (AEs) were reported in 9 (6.7%) participants. No serious AEs were reported during the study. CONCLUSION: Our study findings demonstrated that PG-HPG-based nanoemulsion lubricant eye drops were effective and well tolerated in participants with DED and all of its subtypes. Dove 2020-09-01 /pmc/articles/PMC7478376/ /pubmed/32943837 http://dx.doi.org/10.2147/OPTH.S261318 Text en © 2020 Yeu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yeu, Elizabeth
Silverstein, Steven
Guillon, Michel
Schulze, Marc-Matthias
Galarreta, David
Srinivasan, Sruthi
Manoj, Venkiteshwar
Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
title Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
title_full Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
title_fullStr Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
title_full_unstemmed Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
title_short Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
title_sort efficacy and safety of phospholipid nanoemulsion-based ocular lubricant for the management of various subtypes of dry eye disease: a phase iv, multicenter trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478376/
https://www.ncbi.nlm.nih.gov/pubmed/32943837
http://dx.doi.org/10.2147/OPTH.S261318
work_keys_str_mv AT yeuelizabeth efficacyandsafetyofphospholipidnanoemulsionbasedocularlubricantforthemanagementofvarioussubtypesofdryeyediseaseaphaseivmulticentertrial
AT silversteinsteven efficacyandsafetyofphospholipidnanoemulsionbasedocularlubricantforthemanagementofvarioussubtypesofdryeyediseaseaphaseivmulticentertrial
AT guillonmichel efficacyandsafetyofphospholipidnanoemulsionbasedocularlubricantforthemanagementofvarioussubtypesofdryeyediseaseaphaseivmulticentertrial
AT schulzemarcmatthias efficacyandsafetyofphospholipidnanoemulsionbasedocularlubricantforthemanagementofvarioussubtypesofdryeyediseaseaphaseivmulticentertrial
AT galarretadavid efficacyandsafetyofphospholipidnanoemulsionbasedocularlubricantforthemanagementofvarioussubtypesofdryeyediseaseaphaseivmulticentertrial
AT srinivasansruthi efficacyandsafetyofphospholipidnanoemulsionbasedocularlubricantforthemanagementofvarioussubtypesofdryeyediseaseaphaseivmulticentertrial
AT manojvenkiteshwar efficacyandsafetyofphospholipidnanoemulsionbasedocularlubricantforthemanagementofvarioussubtypesofdryeyediseaseaphaseivmulticentertrial